|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.37 USD | +1.57% |
|
-6.27% | -0.70% |
| 13/01 | Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln | RE |
| 13/01 | Sector Update: Health Care Stocks Lower in Afternoon Trading | MT |
Company Valuation: Sarepta Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 13,454 | 7,841 | 11,375 | 9,021 | 11,614 | 2,239 | 2,239 | - |
| Change | - | -41.72% | 45.06% | -20.7% | 28.75% | -80.72% | 0% | - |
| Enterprise Value (EV) 1 | 12,944 | 6,822 | 10,930 | 8,582 | 11,397 | 2,933 | 2,525 | 2,133 |
| Change | - | -47.29% | 60.21% | -21.48% | 32.79% | -74.27% | -13.9% | -15.54% |
| P/E ratio | -24x | -17.5x | -16.1x | -16.6x | 52x | -4.02x | 10.5x | 11.3x |
| PBR | 17.4x | 8.45x | 29.6x | 10.5x | 7.71x | 1.98x | 1.62x | 1.34x |
| PEG | - | 0.6x | -0.3x | 0.6x | -0x | 0x | -0x | -1.54x |
| Capitalization / Revenue | 24.9x | 11.2x | 12.2x | 7.26x | 6.11x | 1.05x | 1.41x | 1.5x |
| EV / Revenue | 24x | 9.72x | 11.7x | 6.9x | 5.99x | 1.38x | 1.58x | 1.43x |
| EV / EBITDA | -24.1x | -16.2x | -22.1x | -38.4x | 44.6x | -8.08x | 6.77x | 5.86x |
| EV / EBIT | -22.9x | -14.8x | -20.4x | -32x | 52.3x | -7.06x | 8.62x | 8.8x |
| EV / FCF | 512x | -14.2x | -30.7x | -14.9x | -33.3x | -3.97x | 9.23x | 4.21x |
| FCF Yield | 0.2% | -7.06% | -3.26% | -6.72% | -3.01% | -25.2% | 10.8% | 23.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.11 | -5.15 | -8.03 | -5.8 | 2.34 | -5.32 | 2.035 | 1.886 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 540.1 | 701.9 | 933 | 1,243 | 1,902 | 2,127 | 1,594 | 1,493 |
| EBITDA 1 | -537.3 | -421.7 | -494.3 | -223.4 | 255.8 | -362.9 | 373.2 | 364.2 |
| EBIT 1 | -564.2 | -459.7 | -536.2 | -267.8 | 218.1 | -415.5 | 293 | 242.3 |
| Net income 1 | -554.1 | -418.8 | -703.5 | -536 | 235.2 | -534.6 | 250.1 | 222.3 |
| Net Debt 1 | -510.2 | -1,019 | -445.1 | -438.3 | -217.7 | 693.5 | 285.9 | -106.7 |
| Reference price 2 | 170.49 | 90.05 | 129.58 | 96.43 | 121.59 | 21.37 | 21.37 | 21.37 |
| Nbr of stocks (in thousands) | 78,913 | 87,077 | 87,783 | 93,547 | 95,520 | 1,04,787 | 1,04,787 | - |
| Announcement Date | 01/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | 26/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.02x | 1.38x | -8.08x | -.--% | 223.93Cr | |
| -4x | 2.2x | -2.9x | -.--% | 219.09Cr | |
| Average | -4.01x | 1.79x | -5.49x | 0% | 221.51Cr | |
| Weighted average by Cap. | -4.01x | 1.78x | -5.52x | 0% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- SRPT Stock
- Valuation Sarepta Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition